---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-079608"
form_type: "8-K"
ticker: null
cik: "0001618921"
company_name: "Walgreens Boots Alliance, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:11:11.584960+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# WBA Q2 loss per share $6.85 on $5.8B VillageMD impairment; adj EPS $1.20, sales up 6.3%, guidance narrowed to $3.20-3.35

## Summary
- GAAP loss per share $6.85 vs EPS $0.81 YoY; includes $5.8B after-tax non-cash VillageMD goodwill impairment.
- Adjusted EPS $1.20, up 3.4% (2.8% constant currency), on sales $37.1B (+6.3% YoY).
- Fiscal 2024 adjusted EPS guidance narrowed to $3.20-3.35 from prior range; U.S. Healthcare achieved adjusted EBITDA profitability.
- Actions: cost savings target $1B, strategic portfolio review over next 3 months, early wind-down of sale-leaseback program.
- Cencora share sales and challenging retail environment cited as headwinds; lower adjusted effective tax rate provides offset.

## SEC filing metadata
- accession: 0001193125-24-079608
- form_type: 8-K
- cik: 0001618921
- company_name: Walgreens Boots Alliance, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618921/000119312524079608/0001193125-24-079608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618921/000119312524079608/d817592d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-079608
- JSON: https://secwatch.observer/filing/0001193125-24-079608.json
- Plain text: https://secwatch.observer/filing/0001193125-24-079608.txt

## Key facts
- Earnings Releases
  Walgreens Boots Alliance, Inc. reported the fiscal quarter ended February 29, 2024 results: revenue $37.1 billion, EPS $6.85. Guidance reaffirmed.
  - Period: the fiscal quarter ended February 29, 2024
  - Revenue: $37.1 billion
  - EPS: $6.85
  - Guidance: reaffirmed
  - Result: reported results
  source text: basis reflecting lower adjusted effective tax rate** and improved profitability in U.S. Healthcare • Second quarter sales increased 6.3 percent year-over-year to $37.1 billion, up 5.7 percent on a constant currency basis Fiscal 2024 guidance 1 • Narrowing fiscal 2024 adjusted EPS** guidance to $3.20 to $3.35, reflecting challenging retail environment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618921/000119312524079608/0001193125-24-079608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.